Dupixent (dupilumab) — Clinical Medical Policy
Clinical medical policy governing prior authorization and medical necessity criteria for Dupixent (dupilumab) across labeled indications (asthma, COPD, atopic dermatitis, CRSwNP, prurigo nodularis, bullous pemphigoid, chronic spontaneous urticaria, eosinophilic esophagitis) for Anthem members.
Add depemokimab to combination exclusion criteria.
Add new indications for bullous pemphigoid and update quantity limit override for BP.
Update COPD criteria (select review 06/09/2025).
Coverage Criteria and Medical Necessity
Asthma — Initial and Continuation Therapy
Initial requests for Dupixent for asthma may be approved if ALL of the following are met:
Continuation: documented clinical benefit (reduced reliever use, fewer exacerbations, increased FEV1, or symptom reduction) and continued use with ICS-based controller therapy is required.
Chronic Obstructive Pulmonary Disease (COPD) — Initial and Continuation Therapy
Initial requests for Dupixent for COPD may be approved if ALL of the following are met:
Atopic Dermatitis — Initial Therapy
Initial requests for Dupixent for atopic dermatitis may be approved if ALL of the following are met:
Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) — Initial and Continuation Therapy
Initial requests for Dupixent for CRSwNP may be approved if ALL of the following are met:
Asthma — Continuation and Approval Duration
Covered when ALL of the following are met
Approval durations: Initial requests 6 months; continuation 12 months
Atopic Dermatitis — Initial and Continuation
Covered when ALL of the following are met
Continuation: treatment resulted in significant improvement or stabilization (decrease in BSA, pruritus, inflammation, or improved quality of life)
Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) — Initial and Continuation
Covered when ALL of the following are met
Continuation: clinically significant improvement or stabilization and continued use with maintenance intranasal corticosteroids; Approval durations: Initial 6 months; continuation 12 months
Eosinophilic Esophagitis (EoE) — Initial and Continuation
Covered when ALL of the following are met
Continuation: clinically significant improvement or stabilization (including improvement in dysphagia); Approval durations: Initial 6 months; continuation 12 months
Prurigo Nodularis (PN) — Initial and Continuation
Covered when ALL of the following are met
Continuation: clinically significant improvement or stabilization (decreased itching or number/thickness of lesions)
Bullous Pemphigoid (BP) — Initial and Continuation
Covered when ALL of the following are met
Continuation: clinically significant improvement or stabilization (e.g., decreased itching or improved BP lesions)
Chronic Spontaneous Urticaria (CSU) — Initial and Continuation
Covered when ALL of the following are met
Continuation: clinically significant improvement or stabilization and continued use with second‑generation H1 antihistamine therapy; Approval durations: Initial 6 months; continuation 12 months
The policy notes that Dupixent is approved for multiple dermatologic conditions beyond atopic dermatitis, including prurigo nodularis and bullous pemphigoid. However, within the coverage criteria section these additional dermatologic indications are referenced at a high level and the document does not provide the full, specific authorization criteria for those conditions in this extract.
Dupixent will not be approved in combination with certain other immunomodulatory therapies. Specifically, requests for concurrent use with oral or topical JAK inhibitors, other systemic immunosuppressants (for example, cyclosporine, azathioprine, mycophenolate mofetil, or methotrexate), or the listed biologic agents (including ensifentrine, depemokimab, tralokinumab, reslizumab, benralizumab, lebrikizumab, nemolizumab, mepolizumab, tezepelumab, or omalizumab) are excluded from approval.
Requests for Dupixent that do not meet the specified coverage criteria in this policy extract, as well as requests for indications not listed in the criteria, may not be approved. The policy explicitly states that requests outside the described criteria or for other indications are subject to non-approval.
Some reference sections included with this policy extract do not specify additional exclusions. Providers should rely on the exclusions explicitly listed in the clinical criteria section and recognize that the reference material cited does not add further exclusion language in these parts of the document.
Coverage decisions for Dupixent are determined using the policy's clinical review and medical necessity standards. When a request is subject to clinical review (including prior authorization), the criteria in this policy are applied to determine whether the medication meets applicable medical necessity requirements for the intended purpose.
Use of Dupixent in combinations that the policy explicitly disallows (for example, with listed JAK inhibitors, other immunosuppressants, or certain biologics) or use directed to indications not supported by the policy language will not meet the stated coverage criteria. For dermatologic indications referenced in the overview (such as prurigo nodularis and bullous pemphigoid), Dupixent should be prescribed only where the policy’s applicable criteria are met and not in combination with disallowed agents.
The policy indicates that clinical review and medical necessity standards govern determination of non‑medical‑necessity. Specifically, use of Dupixent in combinations explicitly disallowed by the policy or for clinical scenarios that do not meet the stated criteria is considered not medically necessary per the document.
Coding and Clinical Thresholds
| Dupixent (dupilumab) | document subject — biologic medication |
| L12.0 | Bullous pemphigoid |
| L20.0-L20.9 | Atopic dermatitis |
| L28.1 | Prurigo nodularis |
| L50.1 | Idiopathic urticaria |
| L50.8 | Other urticaria |
| L50.9 | Urticaria, unspecified |
| J44.0-J44.9 | Other chronic obstructive pulmonary disease |
| J45.40-J45.52 | Moderate/severe persistent asthma |
| J45.901-J45.998 | Other and unspecified asthma |
| J82.83 | Eosinophilic asthma |
Provider Requirements, Documentation, and Prior Authorization
Prior Authorization Required
Dupixent (dupilumab) requires prior authorization for most indications. Providers must document indication-specific objective findings and prior treatment trials as outlined by the criteria for each condition. Requests lacking required objective test results, required trials of topical or systemic therapies, or exceeding quantity limits are at high risk for denial.
- Prior authorization required for Dupixent across covered indications.
- Ensure documentation aligns with indication-specific criteria (e.g., eosinophil counts, biopsy results, imaging, pulmonary function testing).
- Do not combine Dupixent with disallowed therapies (see policy exclusions).
EoE — Required Documentation
For eosinophilic esophagitis (EoE) initial approval, the provider must document both histologic and clinical criteria: at least 15 intraepithelial eosinophils per high-power field on esophageal biopsy AND symptoms of dysphagia. Also document trials or intolerance to recommended prior therapies when required by criteria (for example, proton pump inhibitors and swallowed topical glucocorticoids when applicable). Continuation approvals require documented clinically significant improvement or stabilization in dysphagia or related symptoms.
- Histology: ≥15 eos/hpf on esophageal biopsy.
- Symptoms: documentation of dysphagia or related clinical symptoms.
- Prior therapy: trial and inadequate response or intolerance to PPI and swallowed topical glucocorticoid where required by criteria.
- Continuation: documentation of clinical improvement or stabilization in dysphagia.
Quantity Limits and Override Criteria
Quantity limits are enforced per product formulation and age/weight definitions. Requests that exceed the stated limits require explicit justification consistent with the policy’s override rules (for initiation dosing or weight-based dosing in EoE).
- 100 mg/0.67 mL syringe: limit = 2 syringes per 28 days.
- 200 mg/1.14 mL pre-filled syringe/pen: limit = 1 per 28 days for ≤11 years; 2 per 28 days for ≥12 years (may approve 2 additional syringes in the first month for initiation when indicated).
- 300 mg/2 mL pre-filled syringe/pen: limit = 1 per 28 days for ≤11 years; 2 per 28 days for ≥12 years (EoE and certain weight-based dosing exceptions allow up to 4 per 28 days as specified).
- Overrides: initiation dosing and weight-based exceptions (e.g., EoE or individuals ≥30–40 kg) may permit additional syringes in the first month or up to 4 syringes per 28 days for EoE per the policy.
Objective Testing and Prior Therapy Documentation
When submitting prior authorization requests, include objective testing for asthma/COPD indications (spirometry with pre/post bronchodilator values and documented FEV1/FVC or FEV1 % predicted) and blood eosinophil counts where required. For CRSwNP include objective confirmation by anterior rhinoscopy, nasal endoscopy, or CT imaging and documentation of trials of intranasal corticosteroids and prior systemic corticosteroids or surgery as applicable.
- Asthma: pretreatment FEV1 ≤80% predicted, FEV1 reversibility ≥12% and ≥200 mL after bronchodilator, and blood eosinophil count ≥150 cells/µL or documented trial of combination controller therapy as required.
- COPD: post-bronchodilator FEV1/FVC <0.7 and post-bronchodilator FEV1 30–70% predicted, blood eosinophils ≥300 cells/µL, and exacerbation/hospitalization history as specified.
- CRSwNP: objective confirmation by anterior rhinoscopy, nasal endoscopy, or CT and documentation of inadequate response to maintenance intranasal corticosteroids and prior systemic corticosteroids or sino-nasal surgery when required.
Denial Risks and Common Reasons for Denial
Denial triggers include missing or inadequate objective data, failure to document required prior therapy trials or contraindications, requests exceeding quantity limits without allowable override justification, and requests combining Dupixent with disallowed agents or immunosuppressants.
- Missing required lab/biopsy/imaging or pulmonary function test results.
- No documented trial or intolerance/contraindication to required prior therapies.
- Request exceeds quantity limits without meeting override criteria.
- Concomitant use with prohibited therapies (listed in exclusions).
Plan and Legal Precedence
Follow federal/state law, contract language, and Plan UM policies; these may take precedence over the clinical criteria in this document. If plan-specific programs or contracts apply, follow those requirements when submitting prior authorization requests.
- Check plan-specific utilization management programs and contract provisions before submission.
- When discrepancies exist between this policy and plan/contract requirements, follow the governing contract or plan program.
Background and Scope
Dupilumab is an interleukin-4 (IL‑4) and interleukin-13 (IL‑13) pathway inhibitor approved for multiple allergic, dermatologic, respiratory, and eosinophilic disorders. The policy overview lists approvals for moderate-to-severe atopic dermatitis, prurigo nodularis, and bullous pemphigoid, and for add-on maintenance therapy in respiratory conditions including asthma, COPD, and chronic rhinosinusitis with nasal polyposis (CRSwNP). The document cites specialty society guidance and clinical trials in support of the indication‑specific criteria and notes that several indications require objective testing (for example, spirometry, blood eosinophil counts, endoscopic or imaging confirmation, or biopsy with eosinophil counts) and prior therapy trials before approval.
Definitions and Clinical Terms
Revision History and Policy Changes
Added depemokimab to the list of agents that may not be combined with Dupixent (combination exclusion criteria).
Added bullous pemphigoid (BP) as a new indication and updated quantity limit override for BP; required continued intranasal steroids in CRSwNP continuation criteria; added 6-month approval duration for chronic spontaneous urticaria; updated EoE prior therapy wording and references.
Updated chronic obstructive pulmonary disease (COPD) specific approval language and criteria.
Added chronic spontaneous urticaria indication and updated quantity limits; added ICD-10-CM codes L50.1, L50.8, L50.9.
Added Vtama to atopic dermatitis criteria and added additional agents (ensifentrine, Ebglyss, Nemluvio) to the do-not-approve list; administrative documentation updates and HCPCS description updates.
Added new indication for COPD.
Updated age criteria for CRSwNP.
Revised prurigo nodularis criteria to include systemic therapies and removed topical overrides; wording and formatting updates.
References
Selected references supporting the clinical criteria and indications include peer‑reviewed trials and specialty guidelines: for example, EoE efficacy data (Lancet Gastroenterol Hepatol), prurigo nodularis trials and consensus guidance, asthma and dermatology guideline sources, and international urticaria guidance. See the cited publications and guideline documents listed in the References section for full bibliographic details.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.